Clinical Trials Search
Clinical Trial 17985
Interventions:INCB024360 (Epacadostat); MEDI4736 (Durvalumab)
Study Type: Treatment
Phase of Study: Phase I/II
- Benjamin Creelan
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCB024360 in Combination With MEDI4736 in Subjects With Selected Advanced Solid Tumors
The primary purposes of this research study is to assess how safe and well tolerated the study drugs Epacadostat and Durvalumab are when combined and given together in patients with previously treated lung cancer, melanoma, head and neck cancer, or pancreatic cancer. The other goals of this study are to determine a tolerated dose of this combination to be further explored, and to assess if these types of cancer respond to the combination of study drugs.
Primary Objectives: Phase 1: To evaluate the safety and tolerability, and define the maximum tolerated dose (MTD) or a pharmacologically active dose (PAD) of INCB024360 administered in combination with MEDI4736 in subjects with select advanced solid tumors. Phase 2: To evaluate the efficacy of INCB024360 administered in combination with MEDI4736 in subjects with select advanced solid tumors by assessing the objective response rate (ORR) per modified RECIST v1.1 (mRECIST v1.1) at the MTD or PAD.